Ruxolitinib

• Myelofibrosis: Treatment Options After Ruxolitinib Failure
• Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study
• JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study
• Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic cancer
• Insights Into Recovery From Acute Fulminant Myocarditis Following Successful Treatment With Ruxolitinib by Comprehensive Single-Cell Profiling
• Acute and chronic graft-versus-host disease treatment and management in the Eastern Mediterranean region: A Worldwide Network for Blood and Marrow Transplantation survey
• Selecting optimal therapy for large granular lymphocytic (LGL) leukemia: current state and future prospects based on molecularly-defined characterization
• Perianal Crohn's Disease Successfully Treated With Topical Ruxolitinib

Eosinophilic phenotypes in polycythemia vera (PV) and essential thrombocythemia (ET) are rare and poorly characterized. Co-occuring JAK2 mutations in cis, specifically both L611S or N622Y mutations, appear to result in a more aggressive clinical phenotype. PV/ET with eosinophilic phenotypes may require full next generation sequencing to capture co-occurring mutations as opposed to more prevalent single gene assays. These eosinophilic phenotypes are highly thrombotic and systemic symptoms appear responsive to early use of the janus kinase (JAK) inhibitor Ruxolitinib ¹⁾.

Ruxolitinib, the first JAK inhibitor approved for clinical use, improves splenomegaly and ameliorates constitutional symptoms in both myelofibrosis and polycythemia vera patients. Ruxolitinib is also useful for controlling hematocrit levels in polycythemia vera patients who were inadequately controlled by conventional therapies. Furthermore, pretransplantation use of ruxolitinib may improve the outcome of allo-hematopoietic stem cell transplantation in myelofibrosis. In contrast to these clinical merits, evidence of the disease-modifying action of ruxolitinib, i.e., reduction of malignant clones or improvement of bone marrow pathological findings, is limited, and many myelofibrosis patients discontinued ruxolitinib due to adverse events or disease progression. To overcome these limitations of ruxolitinib, several new types of JAK inhibitors have been developed. Among them, fedratinib was proven to provide clinical merits even in patients who were resistant or intolerant to ruxolitinib. Pacritinib and momelotinib have shown merits for myelofibrosis patients with thrombocytopenia or anemia, respectively. In addition to treatment for myeloproliferative neoplasms, recent studies have demonstrated that JAK inhibitors are novel and attractive therapeutic options for corticosteroid-refractory acute as well as chronic graft versus host disease ²⁾

1: Rodriguez B, Larsson L, Z'Graggen WJ. Critical Illness Myopathy: Diagnostic Approach and Resulting Therapeutic Implications. Curr Treat Options Neurol. 2022;24(4):173-182. doi: 10.1007/s11940-022-00714-7. Epub 2022 Mar 28. PMID: 35370393; PMCID: PMC8958813.

2: Reed MR, Lyle AG, De Loose A, Maddukuri L, Learned K, Beale HC, Kephart ET, Cheney A, van den Bout A, Lee MP, Hundley KN, Smith AM, DesRochers TM, Vibat CRT, Gokden M, Salama S, Wardell CP, Eoff RL, Vaske OM, Rodriguez A. A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma. Cells. 2021 Dec 2;10(12):3400. doi: 10.3390/cells10123400. PMID: 34943910; PMCID: PMC8699481.

3: Khan S, Mahalingam R, Sen S, Martinez-Ledesma E, Khan A, Gandy K, Lang FF, Sulman EP, Alfaro-Munoz KD, Majd NK, Balasubramaniyan V, de Groot JF. Intrinsic Interferon Signaling Regulates the Cell Death and Mesenchymal Phenotype of Glioblastoma Stem Cells. Cancers (Basel). 2021 Oct 21;13(21):5284. doi: 10.3390/cancers13215284. PMID: 34771447; PMCID: PMC8582372.

4: Zhu H, Jian Z, Zhong Y, Ye Y, Zhang Y, Hu X, Pu B, Gu L, Xiong X. Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation <i>via</i> JAK2/STAT3 Pathway Inhibition. Front Immunol. 2021 Jul 22;12:714943. doi: 10.3389/fimmu.2021.714943. PMID: 34367186; PMCID: PMC8339584.

5: Panagioti E, Kurokawa C, Viker K, Ammayappan A, Anderson SK, Sotiriou S, Chatzopoulos K, Ayasoufi K, Johnson AJ, Iankov ID, Galanis E. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy. J Clin Invest. 2021 Jul 1;131(13):e141614. doi: 10.1172/JCI141614. PMID: 34196308; PMCID: PMC8245183.

6: Tan X, Cao F, Tang F, Lu C, Yu Q, Feng S, Yang Z, Chen S, He X, He J, Weng L, Sun L. Suppression of DLBCL Progression by the E3 Ligase Trim35 Is Mediated by CLOCK Degradation and NK Cell Infiltration. J Immunol Res. 2021 May 24;2021:9995869. doi: 10.1155/2021/9995869. PMID: 34124276; PMCID: PMC8166485.

7: Ding Z, Kloss JM, Tuncali S, Tran NL, Loftus JC. TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance. Neoplasia. 2020 Sep;22(9):352-364. doi: 10.1016/j.neo.2020.06.005. Epub 2020 Jul 3. PMID: 32629176; PMCID: PMC7338993.

8: Delen E, Doğanlar O. The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma- Depended JAK/STAT Signaling Pathway. J Korean Neurosurg Soc. 2020 Jul;63(4):444-454. doi: 10.3340/jkns.2019.0252. Epub 2020 Jun 4. PMID: 32492985; PMCID: PMC7365278.

9: Li S, Yang S, Sun B, Hang C. Melatonin attenuates early brain injury after subarachnoid hemorrhage by the JAK-STAT signaling pathway. Int J Clin Exp Pathol. 2019 Mar 1;12(3):909-915. PMID: 31933900; PMCID: PMC6945149.

10: Delen E, Doganlar O, Doganlar ZB, Delen O. Inhibition of the Invasion of Human Glioblastoma U87 Cell Line by Ruxolitinib: A Molecular Player of miR-17 and miR-20a Regulating JAK/STAT Pathway. Turk Neurosurg. 2020;30(2):182-189. doi: 10.5137/1019-5149.JTN.26122-19.1. PMID: 31452174.

11: Li P, Zhao G, Ding Y, Wang T, Flores J, Ocak U, Wu P, Zhang T, Mo J, Zhang JH, Tang J. Rh-IFN-α attenuates neuroinflammation and improves neurological function by inhibiting NF-κB through JAK1-STAT1/TRAF3 pathway in an experimental GMH rat model. Brain Behav Immun. 2019 Jul;79:174-185. doi: 10.1016/j.bbi.2019.01.028. Epub 2019 Jan 31. Erratum in: Brain Behav Immun. 2020 Aug;88:960-961. PMID: 30711510; PMCID: PMC6591046.

12: Beyer U, Brand F, Martens H, Weder J, Christians A, Elyan N, Hentschel B, Westphal M, Schackert G, Pietsch T, Hong B, Krauss JK, Samii A, Raab P, Das A, Dumitru CA, Sandalcioglu IE, Hakenberg OW, Erbersdobler A, Lehmann U, Reifenberger G, Weller M, Reijns MAM, Preller M, Wiese B, Hartmann C, Weber RG. Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis. Acta Neuropathol. 2017 Dec;134(6):905-922. doi: 10.1007/s00401-017-1774-y. Epub 2017 Oct 13. PMID: 29030706.

13: Liu R, Wang Y, Pu M, Gao J. Effect of alpha lipoic acid on retinal ganglion cell survival in an optic nerve crush model. Mol Vis. 2016 Sep 23;22:1122-1136. PMID: 27703307; PMCID: PMC5040455.

14: Jackson JD, Markert JM, Li L, Carroll SL, Cassady KA. STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells. Mol Cancer Res. 2016 May;14(5):482-92. doi: 10.1158/1541-7786.MCR-15-0427. Epub 2016 Feb 16. PMID: 26883073; PMCID: PMC4867290.